DarioHealth (DRIO) was upgraded to Zacks Rank #2 (Buy), indicating improving earnings expectations and a more favorable analyst view. The note suggests the stock could rise in the near term, but no new operating or financial figures were provided.
DarioHealth (DRIO) was upgraded to Zacks Rank #2 (Buy), indicating improving earnings expectations and a more favorable analyst view. The note suggests the stock could rise in the near term, but no new operating or financial figures were provided.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
